Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1234-1243

  Porter, David L ^a   Connors, Jean M ^a   Van Deerlin, Vivianna M D ^a   Duffy, Kathleen M ^a   McGarigle, Carol ^a   Saidman, Susan L ^a   Leonard, Debra G B ^a   Antin, Joseph H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; RECOMBINANT ALPHA2B INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHIMERA; CLINICAL ARTICLE; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032960701     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1234     Document Type: Article

References (34)

1. Truitt R, Johnson B, McCabe C, et al: Graft versus leukemia, in Ferrara J, Deeg H, Burakoff S (eds): Graft-vs-Host Disease. New York, NY, Marcel Dekker, Inc, 1997, pp 385-424
2. Slavin S, Weiss L, Morecki S, et al: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155-159, 1981
3. Horowitz M, Gale R, Sondel P, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
4. Porter D, Antin J: Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions, in Winter J (ed): Blood Stem Cell Transplantation. Norwell, MA, Kluwer Academic Publishers, 1997, pp 57-86
5. Higano C, Brixey M, Bryant E, et al: Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation: A case report of a probable graft-versus-leukemia effect. Transplantation 50:175-177, 1990
6. Collins R, Rogers Z, Bennett M, et al: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391-395, 1992
7. Odom L, August C, Githens J, et al: Remission of relapsed leukaemia during a graft-versus-host reaction: A "graft-versus-leukaemia reaction" in man? Lancet 2:537-540, 1978
8. Gale R, Horowitz M, Ash R, et al: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646-652, 1994
9. Weiden P, Sullivan K, Flournoy N, et al: Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1533, 1981
10. Apperley J, Mauro F, Goldman J, et al: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect. Br J Haematol 69:239-245, 1988
11. Porter D, Roth M, McGarigle C, et al: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106, 1994
12. Collins R, Shpilberg O, Drobyski W, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
13. Kolb H, Schattenberg A, Goldman J, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
14. Porter D, Orloff G, Antin J: Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 4:11-15, 1994
15. Papadopoulos E, Ladanyi M, Emanuel D, et al: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191, 1994
16. Porter D, Roth M, Lee S, et al: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 18:975-980, 1996
17. Antin J: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273-2277, 1993
18. Balkwill F: Interferons, in Balkwill F (ed): Cytokines in cancer therapy. New York, NY, Oxford University Press, 1989, pp 8-53
19. Upadhyaya G, Gupta S, Sih S, et al: Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88:2131, 1991
20. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplant 18:295-304, 1974
21. Shulman H, Sullivan K, Weiden P, et al: Chronic graft-versus-host syndrome in man: A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 69:204-217, 1980
22. Anderson K, Weinstein H: Transfusion-associated graft-versus-host disease. N Engl J Med 323:315-321, 1990
23. Sykes M, Harty M, Szot G, et al: Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CDS-mediated graft-versus-leukemia effects. Blood 83:2560-2569, 1994
24. Slavin S, Ackerstein A, Weiss L, et al: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221-227, 1992
25. Porter D, Antin J: Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for CML, in McGlave P, Verfaillie C (eds): Hematology-Oncology Clinics of North America. Philadelphia, PA, WB Saunders, Co, 1998, pp 123-150
26. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997
27. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
28. Khouri I, Keating M, Korbling M, et al: Transplant-lite: Induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998
29. Stewart F, Crittenden R, Lowry P, et al: Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 10:2566-2571, 1993
30. Adams P, Davenport R, Reardon D, et al: Detection of circulating donor white blood cells in patients receiving multiple blood transfusions. Blood 80:551-555, 1992
31. Cesano A, Visonneau S, Jeglum K, et al: Phase I clinical trial with a human MHC non-restricted cytotoxic T cell line (TALL-104) in dogs with advanced tumors. Cancer Res 56:3021-3029, 1996
32. Cesano A, Pierson G, Visonneau S, et al: Use of a lethally irradiated major histocompatibility complex nonrestricted cytolytic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Blood 87:393-403, 1996
33. Kohler P, Hank J, Exten R, et al: Response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes: A case report and phase I trial. Cancer 55:552-560, 1985
34. Mastrangelo M, Berd D, Maguire H: Cell mediated immunity: The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol 13:186-194, 1986